1. |
Chakravarthy U, Williams M. The royal college of ophthalmologists guidelines on AMD: executive summary[J]. Eye (Lond), 2013, 27(12): 1429-1431. DOI: 10.1038/eye.2013.233.
|
2. |
Simader C, Ritter M, Bolz M, et al. Morphologic parameters relevant for visual outcome during anti-angio genic therapy of neovascular age-related macular degeneration[J]. Ophthalmology, 2014, 121(6): 1237-1245. DOI: 10.1016/j.ophtha.2013.12.029.
|
3. |
陈曦. Alfibercept在眼科的应用研究进展[J]. 中华实验眼科杂志, 2015, 33(12): 1144-1147. DOI: 10.3760/cma.j.issn.2095-0160.2015.12.020.Chen X. Current advance in the application of alfibercept in ophthalmology[J]. Chin J Exp Ophthalmol, 2015, 33(12): 1144-1147. DOI: 10.3760/cma.j.issn.2095-0160.2015.12.020.
|
4. |
Schmidt-Erfurth U, Kaiser PK, Korobelnik JF, et al. Intravitreal aflibercept injection for neovascular age-rel ated macular degeneration: ninety-six-week results of the VIEW studies[J]. Ophthalmology, 2014, 121(1): 193-201. DOI: 10.1016/j.ophtha.2013.08.011.
|
5. |
Heier JS, Brown DM, Chong V, et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration[J]. Ophthalmology, 2012, 119(12): 2537-2548. DOI: 10.1016/j.ophtha.2012.09.006.
|
6. |
Abri Aghdam K, Seidensticker F, Pielen A, et al. The short-term effects of aflibercept on the size of choroidal neova-scularization lesion in treatment-resistant neovascular age-related macular degeneration as determined by spectral-domain optical coherence tomography[J]. Lasers Surg Med, 2016, 48(7): 668-677. DOI: 10.1002/lsm.22531.
|
7. |
Nagai N, Suzuki M, Uchida A, et al. Non-responsiveness to intravitreal aflibercept treatment in neovascular age-related macular degeneration: implications of serous pigment epithelial detachment[J/OL]. Sci Rep, 2016, 6: 29619[2016-07-11]. https://pubmed.ncbi.nlm.nih.gov/27403807/.DOI: 10.1038/srep29619.
|
8. |
Hatz K, Prünte C. Intravitreal aflibercept in neovascular age-related macular degener -a-tionwith limited response to ranibizumab: a treat-and-extend trial[J]. Retina, 2017, 37(6): 1185-1192. DOI: 10.1097/IAE.0000000000001318.
|
9. |
Spooner K, Hong T, Nair R, et al. Long-term outcomes of switching to aflibercept for treatment-resistant neovascular age-related macular degeneration[J/OL]. Acta Ophthalmol, 2019, 97(5): e706-e712[2019-02-11]. https://pubmed.ncbi.nlm.nih.gov/30740921/.DOI: 10.1111/aos.14046.
|
10. |
赵治, 孙晓东. 关注OCT血管成像检测的CNV血管形态特征动态变化对抗VEGF治疗后新生血管性AMD应答反应的预测作用[J]. 中华实验眼科杂志, 2018, 36(1): 1-4. DOI: 10.3760/cma.j.issn.2095-0160.2018.01.001.Zhao Z, Sun XD. Paying attention to the prognosis guiding effects of CNV dynamic changes based-OCT angiography in neovascular age-related macular degeneration after antiangiogenic therapy[J]. Chin J Exp Ophthalmol, 2018, 36(1): 1-4. DOI: 10.3760/cma.j.issn.2095-0160.2018.01.001.
|
11. |
Tomanek RJ, Hansen HK, Christensen LP. Temporally expressed PDGF and FGF-2 regulate embryonic coronary artery formation and growth[J]. Arterioscler Thromb Vasc Biol, 2008, 28(7): 1237-1243. DOI: 10.1161/ATVBAHA.108.166454.
|
12. |
Motohashi R, Noma H, Yasuda K, et al. Dynamics of inflammatory factors in aqueous humor during ranibizumab or aflibercept treatment for age-related macular degeneration[J]. Ophthalmic Res, 2017, 58(4): 209-216. DOI: 10.1159/000478705.
|
13. |
Kanda A, Noda K, Saito W, et al. Aflibercept traps galectin-1, an angiogenic factor associated with diabetic retinopathy[J/OL]. Sci Rep, 2015, 5: 17946[2015-12-09]. https://pubmed.ncbi.nlm.nih.gov/26648523/.DOI: 10.1038/srep17946.
|
14. |
Hara C, Wakabayashi T, Toyama H, et al. Characteristics of patients with neovascular age-related macular degeneration who are non-responders to intravitreal aflibercept[J]. Br J Ophthalmol, 2018, 103(5): 623-629. DOI: 10.1136/bjophthalmol-2018-312275.
|
15. |
Gale RP, Pearce I, Eter N, et al. Anatomical and functional outcomes following switching from aflibercept to ranibizumab in neovascular age-related macular degeneration in Europe: SAFARI study[J]. Br J Ophthalmol, 2019, 104: 1-7. DOI: 10.1136/bjophthalmol-2019-314251.
|